1.
Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus
by Brunner, Hermine I
Pediatric nephrology (Berlin, West), 2018-08-29, Vol.34 (1), p.117-128
2.
Initial Validation of a Novel Protein Biomarker Panel for Active Pediatric Lupus Nephritis
by SUZUKI, Michiko
Pediatric research, 2009, Vol.65 (5), p.530-536
3.
Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis
by Suzuki, Michiko
Pediatric nephrology (Berlin, West), 2008-01-17, Vol.23 (3), p.403-412
4.
Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus
by Mina, Rina
Annals of the rheumatic diseases, 2014-02, Vol.73 (2), p.401-406
5.
Identification of a urinary proteomic signature for lupus nephritis in children
by Suzuki, Michiko
Pediatric nephrology (Berlin, West), 2007-12, Vol.22 (12), p.2047-2057
6.
Pharmacokinetics of Prednisolone at Steady State in Young Patients With Systemic Lupus Erythematosus on Prednisone Therapy: An Open-Label, Single-Dose Study
by Sagcal-Gironella, Anna Carmela P., MD
Clinical therapeutics, 2011, Vol.33 (10), p.1524-1536
7.
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
by Brunner, Hermine I
Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.1110-1117
8.
Specialized Neuromuscular Training to Improve Neuromuscular Function and Biomechanics in a Patient With Quiescent Juvenile Rheumatoid Arthritis
by Myer, Gregory D
Physical therapy, 2005-08-01, Vol.85 (8), p.791-802
9.
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein
by Ardoin, Stacy P
Annals of the rheumatic diseases, 2014-03, Vol.73 (3), p.557-566
10.
Open-label, single dose pharmacokinetic study of prednisolone at steady state in young patients with SLE on prednisone therapy
by Sagcal-Gironella, Anna Carmela P Anna Carmela P
Clinical therapeutics, 2011-10-01, Vol.33 (10), p.1524-1536
11.
Pediatric rheumatology-its own specialty
by Hinze, Claas
Nature clinical practice. Rheumatology, 2008-06, Vol.4 (6), p.279-279
12.
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations
by Reijnders, Margot R.F
American journal of human genetics, 2016-02-04, Vol.98 (2), p.373-381
13.
Cost-effectiveness analysis of ED decision making in patients with non–high-risk heart failure
by Collins, Sean P., MD, MSc
The American journal of emergency medicine, 2009, Vol.27 (3), p.293-302
14.
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations
by Reijnders, Margot R.F
American journal of human genetics, 2016-02-04, Vol.98 (2), p.373-381
15.
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations
by Reijnders, Margot R. F
American journal of human genetics, 2016-02-04, Vol.98 (2), p.373-381
16.
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations
by Reijnders, Margot R. F
American journal of human genetics, 2016-02-04, Vol.98 (2), p.373-381
